ATE410161T1 - 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen - Google Patents

4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen

Info

Publication number
ATE410161T1
ATE410161T1 AT04750891T AT04750891T ATE410161T1 AT E410161 T1 ATE410161 T1 AT E410161T1 AT 04750891 T AT04750891 T AT 04750891T AT 04750891 T AT04750891 T AT 04750891T AT E410161 T1 ATE410161 T1 AT E410161T1
Authority
AT
Austria
Prior art keywords
carboxyromide
bradykinin
benzoylamino
pyrazole
bromo
Prior art date
Application number
AT04750891T
Other languages
English (en)
Inventor
Jay Tung
Albert Garofalo
Michael Pleiss
Jing Wu
David Wone
Ashley Guinn
Darren Dressen
R Neitz
Jennifer Marugg
Martin Neitzel
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE410161T1 publication Critical patent/ATE410161T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04750891T 2003-05-02 2004-04-30 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen ATE410161T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46769503P 2003-05-02 2003-05-02
US53954604P 2004-01-27 2004-01-27

Publications (1)

Publication Number Publication Date
ATE410161T1 true ATE410161T1 (de) 2008-10-15

Family

ID=33436740

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04750891T ATE410161T1 (de) 2003-05-02 2004-04-30 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen

Country Status (11)

Country Link
US (2) US7417152B2 (de)
EP (1) EP1633348B1 (de)
JP (1) JP2006526015A (de)
AR (1) AR044163A1 (de)
AT (1) ATE410161T1 (de)
CA (1) CA2524269A1 (de)
DE (1) DE602004016992D1 (de)
ES (1) ES2314418T3 (de)
PE (1) PE20050525A1 (de)
TW (1) TW200509910A (de)
WO (1) WO2004098589A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633349A1 (de) * 2003-05-02 2006-03-15 Elan Pharmaceuticals, Inc. 4-bromo-5- (2-chlorobenzoylamino)-1h-pyrazol-3-carbonsäure (1-(aminocarbonyl) eth-1-yl) amid-derivate und verwandte verbindungen als bradykinin-b1-rezeptorantagonisten zur behandlung von entzündlichen erkrankungen
JP2006525361A (ja) * 2003-05-02 2006-11-09 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体アンタゴニストとしての選択された置換ピラゾール誘導体および関連化合物
JP2006526015A (ja) * 2003-05-02 2006-11-16 エラン ファーマシューティカルズ，インコーポレイテッド 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸アミド誘導体および関連化合物
US20060247152A1 (en) * 2005-05-02 2006-11-02 Russ Lebovitz Substituted fullerenes and their use as inhibitors of cell death
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
WO2006071775A2 (en) * 2004-12-29 2006-07-06 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism
JP2008537953A (ja) 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
JP2007191461A (ja) * 2005-05-23 2007-08-02 Japan Tobacco Inc ピラゾール化合物及びそれらピラゾール化合物を含んでなる糖尿病治療薬
AU2006250354A1 (en) * 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
EP2001831A2 (de) * 2006-04-05 2008-12-17 Glaxo Group Limited Verbindungen, die den glycintransporter inhibieren, und anwendungen davon
EP2096111A1 (de) * 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazole und deren verwendung als arzneimittel
EP2196459B1 (de) 2007-09-28 2016-11-02 Takeda Pharmaceutical Company Limited 5-gliedrige heterocyclische verbindung
WO2009099195A1 (ja) 2008-02-08 2009-08-13 Shiseido Company Ltd. 美白剤及び皮膚外用剤
CN102067024B (zh) * 2008-06-17 2013-08-07 日产化学工业株式会社 液晶取向处理剂及使用了该处理剂的液晶显示元件、以及新的二胺
EP2412713B1 (de) 2009-03-26 2016-11-30 Takeda Pharmaceutical Company Limited Pyrazolverbindung
TW201102371A (en) * 2009-03-31 2011-01-16 Zeria Pharm Co Ltd Method for manufacturing benzodiazepine derivative
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
US8859606B2 (en) 2010-07-01 2014-10-14 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US9289365B2 (en) * 2011-10-24 2016-03-22 Avon Products, Inc. Compositions and methods for stimulating collagen synthesis in the skin
US9630945B2 (en) 2012-12-19 2017-04-25 Novartis Ag Autotaxin inhibitors
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
TWI637951B (zh) * 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
ES2791749T3 (es) * 2013-03-15 2020-11-05 Verseon Corp Halogenopirazoles como inhibidores de la trombina
LT2968297T (lt) 2013-03-15 2019-01-10 Verseon Corporation Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai
WO2015016195A1 (ja) 2013-07-29 2015-02-05 協和発酵キリン株式会社 Ｗｎｔシグナル阻害剤
WO2015159175A1 (en) * 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
CN106573006A (zh) * 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
CN106687445A (zh) 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
WO2016105448A1 (en) * 2014-12-22 2016-06-30 Darryl Rideout Imidazoline receptor type 1 ligands for use as therapeutics
RU2017131562A (ru) 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
AU2016340527B2 (en) * 2015-10-23 2020-09-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
JP7208137B2 (ja) 2016-12-09 2023-01-18 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
BR112020000771A2 (pt) 2017-07-14 2020-07-14 F. Hoffmann-La Roche Ag compostos de cetona bicíclica e métodos de uso dos mesmos
AR113811A1 (es) 2017-10-31 2020-06-10 Hoffmann La Roche Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CN113302193A (zh) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
GB201911944D0 (en) * 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) * 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
CN111423377B (zh) * 2020-05-12 2021-06-01 中国药科大学 5-氨基-1h-吡唑衍生物、制备方法及医药用途
IL298316A (en) * 2020-05-20 2023-01-01 Bayer Ag Process for preparing butyl-(5s)-5-({2-[4-(butoxycarbonyl)phenyl]ethyl}[2-(2-{[3-chloro-4'-(trifluoromethyl)[biphenyl]-4-yl) methoxy}phenyl)ethyl]amino)-8,7,6,5-tetrahydroquinoline-2-carboxylate
CA3151034A1 (en) * 2021-03-03 2022-09-03 Kashiv Biosciences, Llc Bioassay method for compounds useful to treat pain
TW202334164A (zh) 2022-01-12 2023-09-01 美商戴納立製藥公司 （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型
EP4482486A4 (de) * 2022-02-23 2026-04-15 Biohaven Therapeutics Ltd Pyrazolylverbindungen als kv7-kanalaktivatoren
WO2023164538A1 (en) * 2022-02-23 2023-08-31 Biohaven Therapeutics Ltd. Pyrazolyl compounds as kv7 channel activators
JP2025507542A (ja) * 2022-02-23 2025-03-21 バイオヘイブン・セラピューティクス・リミテッド Ｋｖ７チャネル活性化剤としてのピラゾリル化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654275A (en) * 1969-10-15 1972-04-04 Pfizer & Co C Quinoxalinecarboxamide antiinflammatory agents
JPS49100080A (de) 1973-02-01 1974-09-20
DE3421386A1 (de) 1984-06-08 1985-12-12 A. Nattermann & Cie GmbH, 5000 Köln Neue n-pyrazolyl-1,2-benzothiazin-3-carboxamide und diese enthaltende pharmazeutische praeparate
JPH03168743A (ja) 1989-11-29 1991-07-22 Konica Corp イミダゾール系染料
GB9416005D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Peptidic compounds analogous to distamycin a and process for their preparation
WO1996014843A2 (en) 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US6433185B1 (en) * 1996-01-11 2002-08-13 Sanofi-Synthelabo N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them
GB2310207A (en) 1996-02-15 1997-08-20 Pharmacia Spa Antiviral ureido derivatives of substituted heterocyclic compounds
AU721037B2 (en) 1996-09-12 2000-06-22 Auckland Uniservices Limited Condensed N-acylindoles as antitumor agents
HUP0001232A3 (en) 1996-12-23 2001-02-28 Elan Pharmaceuticals Inc San F Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds
KR19980057929U (ko) * 1997-02-14 1998-10-26 배순훈 세탁기의 펄세이터
US6562859B1 (en) 1997-12-04 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation
DE19854081A1 (de) * 1998-11-24 2000-05-25 Bayer Ag Substituierte N-Pyrazolyl-phenoxynicotinsäure-(thio)amide
FR2790260B1 (fr) * 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
AU777735B2 (en) 1999-07-15 2004-10-28 Pharmacopeia, Inc. Bradykinin B1 receptor antagonists
DK1268472T3 (da) * 2000-02-07 2004-12-06 Bristol Myers Squibb Co 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
WO2001087888A1 (en) * 2000-05-17 2001-11-22 Sk Chemicals Co., Ltd. Pyrazolopyrimidinone derivatives, process for their preparation and their use
KR20030011371A (ko) * 2000-06-27 2003-02-07 진랩스 테크놀러지스, 인크. 항세균, 항진균 또는 항암 활성을 갖는 신규 화합물
GB0016447D0 (en) 2000-07-04 2000-08-23 Pharmacia & Upjohn Spa Process for preparing distamycin derivatives
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
WO2002008196A1 (en) 2000-07-25 2002-01-31 Sankyo Company, Limited 5-(m-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES
JP2002220376A (ja) * 2000-07-25 2002-08-09 Sankyo Co Ltd ５−（ｍ−シアノベンジルアミノ）ピラゾール誘導体
IT1318696B1 (it) 2000-09-15 2003-08-27 Pharmacia & Upjohn Spa Coniugati di glutatione con derivati della distamicina ad attivita'antitumorale.
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2002099388A2 (en) 2001-06-07 2002-12-12 Merck & Co., Inc. Benzodiazepine bradykinin antagonists
DE10134721A1 (de) 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
BR0207583A (pt) * 2001-12-26 2004-04-27 Genelabs Tech Inc Derivados de poliamida possuindo atividade antibacteriana, antifungo ou antitumor
US20040063658A1 (en) * 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
MXPA05003432A (es) * 2002-10-09 2005-07-05 Pfizer Prod Inc Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos.
JP2006526015A (ja) * 2003-05-02 2006-11-16 エラン ファーマシューティカルズ，インコーポレイテッド 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸アミド誘導体および関連化合物
JP2006525361A (ja) * 2003-05-02 2006-11-09 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体アンタゴニストとしての選択された置換ピラゾール誘導体および関連化合物
EP1633349A1 (de) * 2003-05-02 2006-03-15 Elan Pharmaceuticals, Inc. 4-bromo-5- (2-chlorobenzoylamino)-1h-pyrazol-3-carbonsäure (1-(aminocarbonyl) eth-1-yl) amid-derivate und verwandte verbindungen als bradykinin-b1-rezeptorantagonisten zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
EP1633348A1 (de) 2006-03-15
EP1633348B1 (de) 2008-10-08
US7417152B2 (en) 2008-08-26
ES2314418T3 (es) 2009-03-16
WO2004098589A1 (en) 2004-11-18
US20060281733A1 (en) 2006-12-14
PE20050525A1 (es) 2005-09-08
JP2006526015A (ja) 2006-11-16
US7432379B2 (en) 2008-10-07
WO2004098589A8 (en) 2005-12-08
AR044163A1 (es) 2005-08-24
CA2524269A1 (en) 2004-11-18
TW200509910A (en) 2005-03-16
US20050020659A1 (en) 2005-01-27
DE602004016992D1 (de) 2008-11-20

Similar Documents

Publication Publication Date Title
ATE410161T1 (de) 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
ATE472327T1 (de) Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE371451T1 (de) Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
DE60232029D1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid-derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
ATE331512T1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
DE602004010419D1 (de) Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60328690D1 (de) 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
DE60221569D1 (de) Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
ATE434617T1 (de) 5-amino-4-hydroxy-7-(imidazo ä1,2-aü pyridin-6- ylmethyl)-8-methylnonamidderivate und verwandte verbindungen als renininhibitoren zur behandlung von bluthochdruck
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
DE502005003904D1 (de) Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten
ATE529427T1 (de) Ä1h-indol-5-yl)-heteroaryloxyü-(1-aza-bicyclo- ä3.3.1ü-nonane als cholinergische liganden des n- achr zur behandlung psychotischer und neurodegenerativer leiden
ATE539754T1 (de) Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
DE602004013427D1 (de) Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE435649T1 (de) 4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3- carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen
ATE424199T1 (de) Enalapril-nitroxy-derivate und verwandte verbindungen als ace-hemmer zur behandlung von kardiovaskulären erkrankungen
ATE353693T1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties